BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 31

• 

  Immuno-oncology

  Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers

  As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.

  May 29, 2026

   · 

  4 min read

   · 

  Annalee Armstrong
• 

  China

  Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent

  Pfizer continues its dealmaking spree by striking a back-heavy partnership with China’s Innovent Biologics to assemble a pipeline of antibody-based therapies for cancer.

  May 29, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Regulatory

  FDA delays verdict on Beren’s rare disease drug by three months

  Beren Therapeutics is seeking approval in Neimann-Pick disease type C, an application the FDA was set to decide on by August 17. The new target action date is November 17.

  May 29, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cancer

  Replimune gives cancer immunotherapy a third try after FDA leadership shakeup

  Replimune’s resubmission for RP1 for melanoma comes amid the departures of FDA leaders in place at the time of the drug’s first two rejections, last summer and again in April.

  May 29, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  Cracked gaskets and rust-like residues trigger FDA warning letter to Alchymars

  FDA inspectors found Alchymars failed to adequately maintain equipment used to make active pharmaceutical ingredients for the U.S. market. Over-the-counter drugmakers GC America and Sato Pharmaceutical also received warning letters.

  May 29, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• Press Releases

  Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting

  May 29, 2026

   · 

  4 min read
• Press Releases

  BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

  May 29, 2026

   · 

  13 min read
• Press Releases

  At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

  May 29, 2026

   · 

  6 min read
• Press Releases

  Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

  May 29, 2026

   · 

  7 min read
• Press Releases

  Parexel to Present Real-World Oncology Research and Launch New Patient-Focused Campaign at ASCO 2026

  May 29, 2026

   · 

  5 min read